- Home
- BSBR vs TAK Comparison
BSBR vs TAK Comparison
Compare BSBR & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BSBR | TAK |
|---|---|---|
| Founded | 1985 | 1781 |
| Country | Brazil | Japan |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.3B | 43.3B |
| IPO Year | 2009 | N/A |
Fundamental Metrics
Financial Performance| Metric | BSBR | TAK |
|---|---|---|
| Price | $6.16 | $15.89 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 564.3K | ★ 2.4M |
| Earning Date | 02-04-2026 | 01-29-2026 |
| Dividend Yield | ★ 3.65% | 3.34% |
| EPS Growth | ★ 21.12 | N/A |
| EPS | ★ 0.75 | 0.14 |
| Revenue | $9,251,919,150.00 | ★ $29,846,840,032.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $0.47 |
| P/E Ratio | ★ $8.42 | $113.33 |
| Revenue Growth | ★ 4.43 | N/A |
| 52 Week Low | $3.90 | $12.80 |
| 52 Week High | $6.60 | $15.97 |
Technical Indicators
Market Signals| Indicator | BSBR | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 52.47 | 77.29 |
| Support Level | $6.12 | $15.48 |
| Resistance Level | $6.44 | $15.78 |
| Average True Range (ATR) | 0.12 | 0.17 |
| MACD | 0.03 | 0.05 |
| Stochastic Oscillator | 63.10 | 94.15 |
Price Performance
Historical ComparisonAbout BSBR Banco Santander Brasil SA each representing one unit
Banco Santander (Brasil) SA is part of Santander Group, a Spanish bank. It operates across two segments; the Commercial Banking segment, catering to both individual and corporate client and the Global Wholesale Banking segment, which encompasses Investment Banking and Markets operations, including the Treasury and Equity Business Departments. The bank generates majority of its revenue from the Commercial Banking segment and has operations in Brazil and internationally.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.